Pipeline

LEO Pharma's pipeline reflects the company's long-term focus on R&D and goal to help people achieve healthy skin.

Actinic keratosis

Three studies between phases I and III are under way worldwide. These span new chemical compounds with new mechanisms of action, improved delivery systems and product enhancements.

Psoriasis

Eight topical and systemic studies between phases I and III are under way worldwide. These span new chemical compounds with new mechanisms of action, improved delivery systems, product enhancements and global market expansion. Various clinical activities have been initiated to increase the number of markets for Daivobet® Gel and Daivobet® Ointment for the treatment of body psoriasis. Significant developments include the approval of Daivobet® Gel in Brazil and the completion of the phase III programme for Dovobet® Ointment in Japan.

Eczema/atopic dermatitis

Two topical studies between phases I and III are under way worldwide. These span new chemical compounds with new mechanisms of action and global market expansion.

Thrombosis

An extensive phase III study is under way to meet the need for improved treatment of deep-vein thrombosis in cancer patients.

 

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.